Our Vision & Mission
Restoring Health Through Innovation
iMetabolic Biopharma Corporation is committed to developing safe & effective first in class therapeutics that will enable physicians in their battle against obesity related diseases with a primary focus on hyperlipidemia. Emphasizing patient success; both iMBP management and researchers are focusing on innovation to ensure efficacy, safety and affordability.
Our Team
Management and Board
Dr. Urban A. Kiernan - Founder, CEO and Board Chairman. With almost 20 years of industry business and research experience, Dr. Kiernan is the lead architect in the development of what has now become iMBP. Prior to focusing on iMBP, he was the Director of Biomarker Discovery at Intrinsic Bioprobes Incorporated and later established himself as a Global Business Development Manager for Thermo Fisher Scientific.
Dr. Stephen Naylor - Founder, COO and Board Director. Dr. Naylor has over 30 years of experience in the health and life sciences. He is the former Chief Technology Officer of Beyond Genomics and has held various professional positions at many world renowned academic institutions.
Mr. Bobby Mikkelsen - VP of Finance & Board Director. With over a decade of business accounting & finance experience under his belt, Mr. Mikkelsen brings a new dimension to the team for the execution of iMBP Corporation's developing business strategy. Along with his finance skill and expertise, he provides the company with access to his full service accounting firm for improved operations and ensured compliance of sound accounting practice.
Mr. Jeffrey D. Zimmerman, Esq. - General Counsel & Board Secretary. Mr. Zimmerman has over three decades of business law expertise. His experience ranges from direct business advisement through complex merger and acquisitions. He also has extensive experience through his participation on the Boards of several not for profit organizations.
Business Advisory Board
Mr. André Harrell - CEO; AH2 & Beyond Consulting. With an industrial life science career that spans three decades, Mr. Harrell has worked with many notable Fortune 100 companies such as Johnson & Johnson Inc, Hewlett Packard, BASF, SC Johnson, Bristol Myers Squibb, Mylan Pharmaceutical, Revlon Professional, Twitter, and Novo Nordisk. Through his efforts he has amassed extensive experience in global commercial strategies and corporate development.
Dr. Martin Emanuele - Co-Founder & COO; Visgenx. With over 30 years of bio-pharmaceutical industry experience; including over two decades in senior executive roles in companies that include CytRx Corp., Avanir Pharmaceuticals and Mast Therapeutics, Dr. Emanuale has experience in developing both research and business teams that have resulted in multiple IND and NDA approvals.
Scientific Advisory Board
Dr. Gerald I. Shulman - Research Professor. Howard Hughes Medical Instituite, Yale University School of Medicine
Dr. Michael R. Briggs - President. Woodland Pharmaceuticals, LLC
Dr. Martin Emanuele - Co-Founder. LifeRaft, Inc.
Dr. Randall W. Nelson - Research Professor (Retired). Molecular Biosignatures Analysis Unit, Biodesign, ASU
Dr. Christopher Larson - Vice President & Adjunct Assoc. Professor. Sanford Burnham Presbys Medical Discovery Institute
Dr. Kirkwood A. Pritchard Jr. - Tenured Professor. Medical College of Wisconsin
Medical Advisory Board
Dr. Kitt Falk Petersen - Endocrinologist. Yale University School of Medicine
Dr. Damon Dixon - Cardiologist & Lipidologist. Phoenix Children's Hospital
Dr. H. Randall Craig - Endocrinologist (Fertility Specialist). Fertility Treatment Center